| __timestamp | Apellis Pharmaceuticals, Inc. | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 13774000 |
| Thursday, January 1, 2015 | 6356782 | 22479000 |
| Friday, January 1, 2016 | 4303743 | 27388000 |
| Sunday, January 1, 2017 | 10463151 | 35610000 |
| Monday, January 1, 2018 | 22639184 | 49007000 |
| Tuesday, January 1, 2019 | 67046483 | 61139000 |
| Wednesday, January 1, 2020 | 139401000 | 68836000 |
| Friday, January 1, 2021 | 176771000 | 97592000 |
| Saturday, January 1, 2022 | 277163000 | 106903000 |
| Sunday, January 1, 2023 | 500815000 | 120998000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustainable growth. Apellis Pharmaceuticals, Inc. and Vericel Corporation, two prominent players in the industry, have shown contrasting trends in their SG&A expenses from 2014 to 2023. Apellis Pharmaceuticals has seen a staggering increase of over 17,000% in SG&A expenses, peaking at $500 million in 2023. This reflects their aggressive expansion and investment in marketing and administrative capabilities. In contrast, Vericel Corporation's SG&A expenses have grown more modestly, increasing by approximately 780% over the same period, reaching $121 million in 2023. This suggests a more conservative approach, focusing on steady growth and cost management. These trends highlight the diverse strategies employed by biotech companies to navigate the complexities of the market, offering valuable insights for investors and industry analysts alike.
Amgen Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Amgen Inc. vs Vericel Corporation: SG&A Expense Trends
Regeneron Pharmaceuticals, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
United Therapeutics Corporation vs Vericel Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and Vericel Corporation
Cost Management Insights: SG&A Expenses for Insmed Incorporated and Vericel Corporation
Ultragenyx Pharmaceutical Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Wave Life Sciences Ltd. Trends and Insights
Cost Management Insights: SG&A Expenses for Vericel Corporation and HUTCHMED (China) Limited
Comparing SG&A Expenses: Vericel Corporation vs Amphastar Pharmaceuticals, Inc. Trends and Insights